Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24843108 | 0.88 | DRD4 (0.36) | DRD4RXFP1KLKB1LCK | |
| SCHEMBL24501603 | 0.83 | DRD4 (0.38) | DRD4KLKB1SLC6A4 | |
| SCHEMBL24842084 | 0.83 | IDO1 (0.37) | DRD4RXFP1 | |
| SCHEMBL11155397 | 0.81 | DRD4 (0.40) | DRD4GAAGABRA5 | |
| SCHEMBL11141672 | 0.75 | DRD4 (0.38) | DRD4TLR7LCKSLC6A2 | |
| SCHEMBL9933973 | 0.74 | DRD4 (0.40) | DRD4GAAGABRA5 | |
| SCHEMBL11166846 | 0.73 | DRD4 (0.38) | DRD4TLR7 | |
| SCHEMBL24656020 | 0.73 | DRD4 (0.38) | DRD4GAAGABRA5 | |
| SCHEMBL25253616 | 0.71 | DRD4 (0.39) | DRD4 | |
| SCHEMBL25246743 | 0.71 | SLC6A2 (0.39) | DRD4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | DRD4 3499/4885TLR7 2776/4885RXFP1 4588/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | DRD4 3499/4885TLR7 2776/4885RXFP1 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.